References
- Buchner T, Berdel W E, Wörmann B, Schoch C, Haferlach T, Schnittger S, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol 2005; 56: 247–259
- Lowenberg B, Zittoun R, Kerhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268–1274
- Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise P Y, Tertian G, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272–279
- Tallman M S, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep 2002; 4: 381–389
- Fenaux P, Chevret S, de Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 495–501
- Sanz M A, Vellenga E, Rayón C, Díaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104: 3490–3493
- Latagliata R, Avvisati G, Lo Coco F, Petti M C, Diverio D, Spadea A, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. Ann Oncol 1997; 8: 1273–1275
- Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al. Treatment of elderly patients (>or = 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17: 1085–1090
- Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005; 19: 230–233
- Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell R P, Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–296
- Ades L, Raffoux E, Chevret S, de Botton S, Guerci A, Pigneux A, et al. Is AraC required in the treatment of newly diagnosed APL? Results of a randomized trial (APL 2000). Blood 2004; 104: 115a
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
- Sanz B M, Carli P M, Maloisel F, Thomas X, Detourmignies L, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123–2137
- Gupta V, Chun K, Yi Q -L, Minden M, Schuh A, Wells R, et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 03: 2082–2090